Present and Upcoming Coding, Reimbursement, and Compliance Issues
Wednesday, April 21, 2021
2:00 - 3:15 pm ET
As a nation, we have endured the COVID-19 pandemic for well over a year. From the beginning, both international and domestic governing bodies have stressed the importance of diagnostic testing as part of the comprehensive strategy to combat COVID-19. As laboratories created and improved COVID-19 testing programs, the AMA, CMS, CDC, and federal payers scrambled to develop applicable coding, reimbursement, and coverage rules and policies. This CodeMap® Webinar will review the existing and developing rules that labs must follow to submit claims, get paid, and remain in compliance. In addition, our experts will explore potential issues that may develop in the coming months and years. This CodeMap® Webinar will address the following:
- Coding and Medicare Reimbursement: Make sure your laboratory understands all the new codes and reimbursement concerning COVID-19 testing and associated services. Also, you must understand all applicable payment policies created by CMS and its contractors. Finally, our experts will discuss the future of proprietary and temporary HCPCS codes used to report COVID-19 testing.
- Public Health Emergency (PHE): The DHHS has extended the PHE for COVID-19 four times since January 31, 2020. As long as the PHE is in place, federal agencies are waiving many reporting and oversight requirements. Our experts will discuss when this might end and what it means for clinical laboratories.
- Future Testing Trends: Even after the PHE ends, the demand for COVID-19 testing will continue. We will examine how this testing may be used to determine vaccine effectiveness, perform public health surveillance, monitor workplace safety, and prevent spread of the virus in conjunction with large events and travel. We will also discuss which types and/or combination of testing will be used including molecular tests, antigen tests, and antibody tests.
- Compliance Considerations: During the pandemic, enforcement actions involving COVID-19 testing have been limited. Do not expect that to continue much longer. Laboratories must understand how to comply with the rules and requirements concerning high-throughput testing, panels including COVID-19 tests and other respiratory pathogens, medical necessity, and who may order COVID-19 tests.